Prognostic Value of Histidine-Rich Glycoprotein for Community-Acquired Pneumonia

Figure 1

Levels of histidine-rich glycoprotein (HRG) across multiple groups. (a) Levels of HRG in patients with community-acquired pneumonia (CAP) and healthy volunteers. In CAP patients, nonsevere vs. severe CAP, ; non-CAP patients vs. healthy volunteers, . (b) Levels of HRG in healthy volunteers and CAP patients grouped by prognoses. Survivors vs. healthy volunteers, ; survivors vs. nonsurvivors, . (c) Comparison of HRG in CAP patients grouped by days of hospitalization (0-7 days, 8-14 days, 15-30 days, and ≥31 days). Intergroup comparison, . (d) Comparison of HRG in CAP patients for different etiologies: bacteria, virus, atypical pathogen (including Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila), mixed pathogen, and unknown pathogen. Intergroup comparison, .

(a)

(b)

(c)

(d)